Hem Pharma, Inc.
KKRX:37627027,850.00
KRW
-300.00
(-1.07%)
ISIN
KR7376270005
Return %
Stock
S&P 500
1Y
-5.91
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Yosep Ji
- Full Time Employees
- 101
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Suwon-si South Korea
- IPO Date
- Nov 5, 2024
- Website
- hempharma.bio
- Similar Companies
- Business
- HEM Pharma, Inc. is a South Korea-based biotechnology company that discovers, develops, and commercializes microbiome-based personalized healthcare solutions and live biotherapeutic products (LBPs). Founded in 2016 and headquartered in Pohang, South Korea, the company leverages its proprietary Pharmaceutical Meta-Analytical Screening (PMAS) technology—a high-throughput in vitro simulation platform that replicates individual gut environments to analyze host-microbe interactions and screen customized functional compounds. HEM Pharma operates across three primary business segments: Personalized Healthcare, Live Biotherapeutic Products (LBPs), and Contract Development and Manufacturing Organization (CDMO) Services. The company offers a comprehensive portfolio of products and services, comprising personalized gut microbiome analytics and tailored probiotic formulations marketed under the myLAB and myLAB PLUS brands in partnership with Amway; AI-integrated health management solutions, including the BiGNAL platform and smart monitoring systems that track bowel activity and generate personalized dietary and lifestyle recommendations; clinical-stage live biotherapeutic drug candidates, including HEMP-001, a psychobiotic formulation in clinical development for major depressive disorder, and HEMP-002, a therapeutic candidate targeting low anterior resection syndrome (LARS), alongside discovery programs in dermabiotics, pulmobiotics, and metabolic disorders; and end-to-end CDMO services covering microbial strain isolation, characterization, banking, high-density fermentation, formulation development, and Good Manufacturing Practice (GMP)-compliant production of probiotic and microbiome-based materials from its dedicated manufacturing facilities in Sejong, South Korea. The company primarily serves consumers, healthcare professionals, dietary supplement brand owners, and pharmaceutical collaborators across domestic and international markets. In recent developments, HEM Pharma completed its initial public offering and listed its common stock on the KOSDAQ market (KRX: 376270) under South Korea's technology-growth special listing framework in November 2024. The company has substantially broadened its strategic collaboration with global health and wellness company Amway to expand the commercial distribution of its myLAB personalized microbiome solutions into international markets, including the United States, Japan, Thailand, Malaysia, and Taiwan. To strengthen its digital health capabilities, HEM Pharma acquired Log(me), an artificial intelligence healthcare software enterprise, integrating predictive AI algorithms with its multi-omics microbiome database. Furthermore, the company secured KRW 54 billion in capital financing to construct a second specialized GMP production facility in Sejong, expanding its CDMO capacity for clinical and commercial biopharmaceutical supply. Clinically, HEM Pharma achieved key regulatory milestones by securing U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance to advance HEMP-001 into Phase 2a clinical trials for depression and obtaining Australian clinical trial approval for Phase 2a evaluation of HEMP-002 for LARS.